Presence of activating KRAS mutations correlates significantly with expression of tumour suppressor genes DCN and TPM1 in colorectal cancer

BMC Cancer

Volumn 9, Issue , 2009, Pages 282-

  Mlakar, Vid ^a   Berginc, Gašper ^a   Volavšek, Metka ^a   Štor, Zdravko ^b   Rems, Miran ^c   Glavač, Damjan ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^c Jesenice Hospital   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TROPOMYOSIN; CARRIER PROTEIN; DECORIN; K RAS PROTEIN; MESSENGER RNA; SOLUTE CARRIER FAMILY 26 MEMBER 3 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CHROMOSOME ABERRATION; COLON CARCINOGENESIS; COLORECTAL CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; GENE DELETION; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; HUMAN; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; TUMOR SUPPRESSOR GENE;

COLORECTAL NEOPLASMS; DECORIN; EXTRACELLULAR MATRIX PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MUTATION; PROTEOGLYCANS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TROPOMYOSIN;

EID: 70349868190     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-282     Document Type: Article

References (42)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics, 2005. CA Cancer J Clin 2005, 55:10-30. 10.3322/canjclin.55.1.10, 15661684.
2. Goldberg RM, Gill S. Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancer. Cancer Chemother Pharmacol 2004, 54(Suppl 1):S57-64.
3. Worthley DL, Whitehall VL, Spring KJ, Leggett BA. Colorectal carcinogenesis: Road maps to cancer. World J Gastroenterol 2007, 13:3784-3791.
4. Grady WM. Genomic instability and colon cancer. Cancer Metastasis Rev 2004, 23:11-27. 10.1023/A:1025861527711, 15000146.
5. Smith G, Carey FA, Beattie J, Wilkie MJ, Lightfoot TJ, Coxhead J, Garner RC, Steele RJ, Wolf CR. Mutations in APC, Kirsten-ras, and p53 - alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci USA 2002, 99:9433-9438. 10.1073/pnas.122612899, 123158, 12093899.
6. Conlin A, Smith G, Carey FA, Wolf CR, Steele RJ. The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut 2005, 54:1283-1286. 10.1136/gut.2005.066514, 1774675, 15843421.
7. Fearnhead NS, Britton MP, Bodmer WF. The ABC of APC. Hum Mol Genet 2001, 10:721-733. 10.1093/hmg/10.7.721, 11257105.
8. Lynch HT, Smyrk T, Lynch JF. Overview of natural history, pathology, molecular genetics and management of HNPCC (Lynch Syndrome). Int J Cancer 1996, 69:38-43. 10.1002/(SICI)1097-0215(19960220)69:1<38::AID-IJC9>3.0.CO;2-X, 8600057.
9. Lievere A, Bachet J-B, Corre DL, Boige V, Landi B, Emile J-F, Cote J-F, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, Laurent-Puig P. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006, 66:3992-3995. 10.1158/0008-5472.CAN-06-0191, 16618717.
10. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, Bastit L, Killian A, Sesboüé R, Tuech JJ, Queuniet AM, Paillot B, Sabourin JC, Michot F, Michel P, Frebourg T. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007, 96:1166-1169. 10.1038/sj.bjc.6603685, 17375050.
11. König EA, Köves I, Raşinariu A, Popp AR, Kusser WC, Soyonki K, Kovács A, Glickman BW, Jeney A, Marcsek ZL. Alterations of K-ras and p53 mutations in colorectal cancer patients in Central Europe. J Toxicol Environ Health A 2001, 62:333-347. 10.1080/152873901300018057, 11261896.
12. Ravnik-Glavac M, Glavac D, Dean M. Sensitivity of single-strand conformation polymorphism and heteroduplex method for mutation detection in the cystic fibrosis gene. Hum Mol Genet 1994, 3:801-807. 10.1093/hmg/3.5.801, 7521710.
13. Glavac D, Dean M. Optimization of the single-strand conformation polymorphism (SSCP) technique for detection of point mutations. Hum Mutat 1993, 2:404-414. 10.1002/humu.1380020513, 8257994.
14. Ki DH, Jeung HC, Park CH, Kang SH, Lee GY, Lee WS, Kim NK, Chung HC, Rha SY. Whole genome analysis for liver metastasis gene signatures in colorectal cancer. Int J Cancer 2007, 121:2005-2012. 10.1002/ijc.22975, 17640062.
15. Alon U, Barkai N, Notterman DA, Gish K, Ybarra S, Mack D, Levine AJ. Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays. Proc Natl Acad Sci USA 1999, 96:6745-6750. 10.1073/pnas.96.12.6745, 21986, 10359783.
16. Notterman DA, Alon U, Sierk AJ, Levine AJ. Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. Cancer Res 2001, 61:3124-3130.
17. Graudens E, Boulanger V, Mollard C, Mariage-Samson R, Barlet X, Grémy G, Couillault C, Lajémi M, Piatier-Tonneau D, Zaborski P, Eveno E, Auffray C, Imbeaud S. Deciphering cellular states of innate tumor drug responses. Genome Biol 2006, 7:R19. 10.1186/gb-2006-7-3-r19, 1557757, 16542501.
18. Zou TT, Selaru FM, Xu Y, Shustova V, Yin J, Mori Y, Shibata D, Sato F, Wang S, Olaru A, Deacu E, Liu TC, Abraham JM, Meltzer SJ. Application of cDNA microarrays to generate a molecular taxonomy capable of distinguishing between colon cancer and normal colon. Oncogene 2002, 21:4855-4862. 10.1038/sj.onc.1205613, 12101425.
19. van Krieken JHJM, Jung A, Kirchner T, Carneiro F, Seruca R, Bosman FT, Quirke P, Fléjou JF, Plato Hansen T, de Hertogh G, Jares P, Langner C, Hoefler G, Ligtenberg M, Tiniakos D, Tejpar S, Bevilacqua G, Ensari A. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 2008, 453:417-431. 10.1007/s00428-008-0665-y, 18802721.
20. Schweinfest CW, Henderson KW, Suster S, Kondoh N, Papas TS. Identification of a colon mucosa gene that is down-regulated in colon adenomas and adenocarcinomas. Proc Natl Acad Sci USA 1993, 90:4166-4170. 10.1073/pnas.90.9.4166, 46467, 7683425.
21. Höglund P, Haila S, Socha J, Tomaszewski L, Saarialho-Kere U, Karjalainen-Lindsberg ML, Airola K, Holmberg C, de la Chapelle A, Kere J. Mutations of the Down-regulated in adenoma (DRA) gene cause congenital chloride diarrhoea. Nat Genet 1996, 14:316-319. 10.1038/ng1196-316, 8896562.
22. Kere J, Lohi H, Höglund P. Genetic Disorders of Membrane Transport III. Congenital chloride diarrhea. Am J Physiol 1999, 276:G7-G13.
23. Hemminki A, Höglund P, Pukkala E, Salovaara R, Järvinen H, Norio R, Aaltonen LA. Intestinal cancer in patients with a germline mutation in the down-regulated in adenoma (DRA) gene. Oncogene 1998, 16:681-684. 10.1038/sj.onc.1201538, 9482116.
24. Chapman JM, Knoepp SM, Byeon MK, Henderson KW, Schweinfest CW. The colon anion transporter, down-regulated in adenoma, induces growth suppression that is abrogated by E1A. Cancer Res 2002, 62:5083-5088.
25. Antalis TM, Reeder JA, Gotley DC, Byeon MK, Walsh MD, Henderson KW, Papas TS, Schweinfest CW. Down-regulation of the down-regulated in adenoma (DRA) gene correlates with colon tumor progression. Clin Cancer Res 1998, 4:1857-1863.
26. Yamaguchi Y, Ruoslahti E. Expression of human proteoglycan in Chinese hamster ovary cells inhibits cell proliferation. Nature 1988, 336:244-246. 10.1038/336244a0, 3194009.
27. Santra M, Skorski T, Calabretta B, Lattime EC, Iozzo RV. De novo decorin gene expression suppresses the malignant phenotype in human colon cancer cells. Proc Natl Acad Sci USA 1995, 92:7016-7020. 10.1073/pnas.92.15.7016, 41462, 7624361.
28. Seidler DG, Goldoni S, Agnew C, Cardi C, Thakur ML, Owens RT, McQuillan DJ, Iozzo RV. Decorin protein core inhibits in vivo cancer growth and metabolism by hindering epidermal growth factor receptor function and triggering apoptosis via caspase-3 activation. J Biol Chem 2006, 281:26408-26418. 10.1074/jbc.M602853200, 16835231.
29. De Luca A, Santra M, Baldi A, Giordano A, Iozzo RV. Decorin-induced growth suppression is associated with up-regulation of p21, an inhibitor of cyclin-dependent kinases. J Biol Chem 1996, 271:18961-18965. 10.1074/jbc.271.46.28738, 8702560.
30. Ständer M, Naumann U, Wick W, Weller M. Transforming growth factor-beta and p-21: multiple molecular targets of decorin-mediated suppression of neoplastic growth. Cell Tissue Res 1999, 296:221-227. 10.1007/s004410051283, 10382266.
31. Augoff K, Rabczynski J, Tabola R, Czapla L, Ratajczak K, Grabowski K. Immunohistochemical study of decorin expression in polyps and carcinomas of the colon. Med Sci Monit 2008, 14:CR530-5.
32. Arends JR. Molecular interactions in the Vogelstein model of colorectal carcinoma. J Pathol 2000, 190:412-416. 10.1002/(SICI)1096-9896(200003)190:4<412::AID-PATH533>3.0.CO;2-P, 10699988.
33. Jaffe AB, Hall A. Rho GTPases in transformation and metastasis. Adv Cancer Res 2002, 84:57-80. full_text, 11883532.
34. Bhattacharya B, Prasad GL, Valverius EM, Salomon DS, Cooper HL. Tropomyosins of human mammary epithelial cells: consistent defects of expression in mammary carcinoma cell lines. Cancer Res 1990, 50:2105-2112.
35. Wang FL, Wang Y, Wong WK, Liu Y, Addivinola FJ, Liang P, Chen LB, Kantoff PW, Pardee AB. Two differentially expressed genes in normal human prostate tissue and in carcinoma. Cancer Res 1996, 56:3634-3637.
36. Braverman RH, Cooper HL, Lee HS, Prasad GL. Anti-oncogenic effects of tropomyosin: isoform specificity and importance of protein coding sequences. Oncogene 1996, 13:537-545.
37. Prasad GL, Fuldner RA, Cooper HL. Expression of transduced tropomyosin 1 cDNA suppresses neoplastic growth of cells transformed by the ras oncogene. Proc Natl Acad Sci USA 1993, 90:7039-7043. 10.1073/pnas.90.15.7039, 47071, 8346214.
38. Kahl CR, Means AR. Regulation of cell cycle progression by calcium/calmodulin-dependent pathways. Endocr Rev 2003, 24:719-736. 10.1210/er.2003-0008, 14671000.
39. Choi J, Husain M. Calmodulin-mediated cell cycle regulation: new mechanisms for old observations. Cell Cycle 2006, 5:2183-2186.
40. Kortvely E, Gulya K. Calmodulin, and various ways to regulate its activity. Life Sci 2004, 74:1065-1070. 10.1016/j.lfs.2003.07.026, 14687647.
41. Palfi A, Kortvely E, Fekete E, Kovacs B, Varszegi S, Gulya K. Differential calmodulin gene expression in the rodent brain. Life Sci 2002, 70:2829-2855. 10.1016/S0024-3205(02)01544-8, 12269397.
42. Toutenhoofd SL, Strehler EE. The calmodulin multigene family as a unique case of genetic redundancy: multiple levels of regulation to provide spatial and temporal control of calmodulin pools?. Cell Calcium 2000, 28:83-96. 10.1054/ceca.2000.0136, 10970765.